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Abstract
Female sex/gender is an undercharacterized variable in studies
related to lung development and disease. Notwithstanding, many
aspects of lung and sleep biology and pathobiology are impacted by
female sex and female reproductive transitions. These may manifest
as differential gene expression or peculiar organ development. Some
conditions are more prevalent in women, such as asthma and
insomnia, or, in the case of lymphangioleiomyomatosis, are seen
almost exclusively in women. In other diseases, presentation differs,
such as the higher frequency of exacerbations experienced by women
with chronic obstructive pulmonary disease or greater cardiac
morbidity among women with sleep-disordered breathing. Recent
advances in -omics and behavioral science provide an opportunity to
specifically address sex-based differences and explore research needs
and opportunities that will elucidate biochemical pathways, thus
enabling more targeted/personalized therapies. To explore the status
of and opportunities for research in this area, the NHLBI, in
partnershipwith theNIHOffice of Research onWomen’sHealth and
the Office of Rare Diseases Research, convened a workshop of
investigators in Bethesda, Maryland on September 18 and 19,
2017. At the workshop, the participants reviewed the current
understanding of the biological, behavioral, and clinical implications
of female sex and gender on lung and sleep health and disease, and
formulated recommendations that address research gaps, with a
view to achieving better health outcomes through more precise
management of female patients withnonneoplastic lung disease. This
report summarizes those discussions.
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Introduction to the Role of
Female Sex and Gender in
Lung/Sleep Health and
Disease
The NIH is committed to improving the
health of all individuals. Central to this
mission is supporting research that informs
prevention and treatment strategies for
both men and women. The role of sex
and gender in scientific discovery, disease
detection, diagnosis, and treatment is often
underappreciated. To this end, the NHLBI,
in partnership with the NIH Office of
Research on Women’s Health and the
Office of Rare Diseases Research, convened
a 2-day workshop of investigators in
Bethesda, Maryland in September 2017. At
the workshop, the participants, chosen
based on their expertise in women’s
health as it applies to various aspects of
lung and sleep medicine, reviewed the
current understanding of the biological,
behavioral, and clinical implications of
female sex and gender on lung and
sleep health and disease. Topics were
chosen by the NHLBI and workshop
chairs. Experts presented data with
subsequent discussion. After the workshop,
electronic discussions continued with
participants formulating recommendations
that address research gaps, with a view
to achieving better health outcomes
through more precise management of
female patients with nonneoplastic lung
disease.
Central to these discussions at the
outset was to be precise regarding the
difference between the terms “sex” and
“gender.” Whereas “sex” refers to biological
differences between females and males,
including chromosomes, sex organs, and
endogenous hormonal profiles, “gender”
refers to socially constructed and enacted
roles and behaviors, which occur in a
historical and cultural context and vary not
only across societies and over time, but may
also impact individuals differently across
the lifespan. Gender encompasses factors,
such as social support, environmental
exposures, and work roles (i.e., shift work
exposure causing circadian misalignment is
prevalent in women). Ultimately, health is
influenced by the interactions between both
sex and gender. However, including women
and diverse populations in research is not
just a matter of enrolling women and
diverse populations in clinical studies, but
requires changing current paradigms of
how research is designed. Researchers must
consider the impact that their experimental
design has on the sex hormonal profile and
accurately analyze data focusing on the
impact of sex, not only of the individual
being studied, but also of the cell used in an
in vitro experiment. Treating all adults as
equivalent, drawing conclusions devoid of
sex, gender, age, race, and environment, is
imprecise, and focusing research only on
one sex or gender to the exclusion of the
other is no longer acceptable (1). Exploring
the potential influences of both sex and
gender on lung and sleep research is the
focus of this report.
Biological Domains through
Which Sex and Gender
Impact Health and Disease
Sex Hormones in Lung Development
and Disease
Inherent sex differences in human lung
structure and function are apparent even
in utero, and manifest throughout the
lifespan (2). Sex differences in lung
structure/function at puberty, pregnancy,
menopause, and in aging suggest additional
modulatory roles of sex steroids (estrogen,
progesterone, testosterone) and/or their
metabolites. Relationships between sex
steroids and lung structure/function are
underscored by sex differences in
susceptibility to and incidence and severity
of, for example, asthma, chronic obstructive
pulmonary disease (COPD), pulmonary
fibrosis, lung cancers, and pulmonary
hypertension. A greater female-to-male
ratio, or worse outcomes in women,
emphasize the need to understand the
relative roles of intrinsic sex differences
versus the roles of sex steroids per se
(particularly female sex steroids) in disease
pathophysiology. Appreciation of how sex
steroids or their metabolites exert their
action, both as gonadally derived hormones
and locally produced, may be important.
Furthermore, it is necessary to understand
the likely substantial cellular, tissue, or
even species heterogeneity in basic sex
steroid and receptor signaling pathways,
as well as interactions between sex
steroids. Understanding the role of sex
steroid signaling in the lung could
contribute to development of novel
biomarkers and therapeutic strategies to
target lung diseases (3).
Tobacco Use, Sex/Gender, and Lung
Disease
Tobacco use is the leading cause of
preventable morbidity and mortality in the
United States, resulting in roughly 500,000
deaths yearly (4). The disease risks from
smoking by women, including lung disease,
have risen sharply over the last 50 years,
and are now equal to those for men (5).
Historically, males have initiated tobacco
substance abuse at earlier ages and in
higher proportions than females (6),
although current smoking prevalence for
teenage boys and girls is roughly similar
(7). Unfortunately, the age of smoking
initiation for most adults who smoke is
before 18 years of age (7). Limited reports
suggest that early tobacco initiation may be
associated with delayed puberty in both
girls and boys (8, 9). The U.S. Food and
Drug Administration has outlined a
strategy to reduce tobacco-related disease,
which includes minimizing the abuse
liability of cigarettes, and investigating
whether “less harmful” tobacco/nicotine
products can support this public health goal
(10). It is critical to understand whether
this approach would be equally effective for
women and men. The U.S. Food and Drug
Administration is also supporting research
evaluating whether reduced-nicotine
cigarettes translate to reductions in
smoking behavior. It is more difficult for
women to quit smoking, and women’s
smoking behavior is less tied to nicotine
content and nicotine-related reinforcement.
Continued research designed to investigate
sex and gender differences in response to
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reduced-nicotine-content cigarettes is
critical. The prevalence of e-cigarette use
continues to increase, especially among
adolescents. There is much conflicting data
about whether e-cigarettes contribute to
smoking cessation behavior, and it is
unknown whether there are sex differences
in these relationships or in their health
impact. Animal models of tobacco exposure
have just begun to explore some of these
issues.
Circadian Rhythms, Sex/Gender, and
Lung Disease
Circadian rhythms are endogenous
variations in physiology resulting from
feedback loops that produce rhythms
in gene expression with a cycle length
of approximately 24 hours (11). The
suprachiasmatic nucleus, a master
pacemaker in the hypothalamus, receives
light/dark information, synchronizes this
system to the 24-hour solar day, and then
transmits timing information to the rest of
the body via autonomic and endocrine
signals. Cells, tissues, and organs of the
body also receive circadian timing
information from feeding and other
behaviors. When synchronized and
optimally timed, the circadian system
allows the body to anticipate and prepare
for regular physiologic challenges (11).
However, access to artificial light, irregular
sleep schedules, travel across time zones,
shift work, and other aspects of modern
24/7 society can desynchronize these
rhythms, resulting in suboptimal
functioning in the short term and,
over the longer term, increase the risk
of cardiovascular disease, diabetes,
cancer, depression, and reproductive
complications, among other conditions
affecting women. Sex differences in key
features of the human circadian system
may result in differential susceptibility to
circadian misalignment, circadian rhythm
sleep disorders, and circadian-coupled
pathophysiology disease risk in men and
women (12). In fact, in a clinical study
where sleep–wake cycle was purposefully
disrupted, women experienced more
cognitive impairment than men, suggesting
that women may be more susceptible to the
effects of shift work and jet lag (13). Nearly
half of protein-coding genes show circadian
expression, and there is major overlap of
those genes with disease-associated genes
and molecular targets of medications. These
discoveries may be leveraged to identify
circadian-dependent molecular signatures
and mechanisms of disease pathophysiology
to improve the prevention and management
of diseases affecting women’s health across
the lifespan (14).
Microbiome, Sex/Gender, and Lung
Disease
The human microbiome, a complex system
comprised of bacteria, viruses, fungi, and
archaea that inhabit various niches, plays a
role in a number of diseases, including
cardiovascular disease, diabetes, obesity,
and cancer. Several reasons point to a
potential influence of sex and gender on the
microbiome. Differences in anatomy,
environmental exposures, hormones, and
medications may alter both the types of
microbes present at a given body site and
their functions. Cross-talk between the host
and microbes may occur via effects of
sex hormones on bacterial growth and
signaling, as well as through bacterial
metabolism of sex hormones. The
microbiome may also differ over the
lifespan and across reproductive phases,
such as puberty, pregnancy, and
menopause. There may also be sex
differences in the microbial community
structure and function in the gut, where
most microbiome studies have so far been
focused. The microbiome of the lung is
less-well understood. Investigators are
exploring the role of the lung microbiome
in diseases, such as asthma, cystic fibrosis
(CF), and COPD, but very little has been
reported about the influence of sex and
gender. A study of patients with CF found
that exacerbations increased during the
menstrual cycle in correspondence of
higher estradiol levels, and women
taking oral contraceptives had fewer
exacerbations (15). In a mouse asthma
model of vitamin D supplementation,
investigators reported that the lung
microbiome differed in male and female
mice (16).
Animal and Cellular Models of Lung
Disease and Sex/Gender
Understanding of the biology and
pathobiology of lung disease has been
greatly enhanced by the availability of
animal models of lung diseases (17).
However, many variables in mouse
experimental models, including sex, can
confound comparisons among papers
published from different groups, but
often go unreported. It is critical that
investigators provide detailed reporting
of their model(s). This is of particular
importance when modeling lifespan stages
(puberty, adulthood, old age) in animal
models. Asthma is a prime example where
discrepancies exist in the literature (18).
Due to differences in lung structure, the
inflammatory response, and airway
hyperresponsiveness to allergens in mouse
versus human lungs, developing animal
models that attempt to more closely
resemble different human asthma
endotypes is warranted (19). There is a
need to better model and understand
the effect of female sex and obesity on
allergic lung inflammation, as well as
premenstrual exacerbations, de novo
asthma postmenopause, and severe
steroid-resistant asthma (20, 21). Animal
models have also been widely used to
study tobacco smoke exposure (22, 23),
but there is a scarcity of experimental data
on sex differences. Evidence suggests that
increased small airway wall remodeling
is observed in female compared with
male mice (24, 25). Data on airspace
enlargement are less conclusive, with
reports that cigarette smoke–induced
emphysema occurs more readily in female
compared with male mice, whereas other
studies did not observe differences
between sexes (26, 27). Clearly, further
studies are warranted to assess sex
differences in animal models of COPD.
These same principles are relevant to cell
lines where sex, age, time of collection, and
culture conditions must also be carefully
considered and detailed (28). The products
of the X and Y genes include functions
beyond those related to development
of sex hormones. Differential gene
expression by sex has been noted in many
tissues, and may have marked impact on
biology. However, a review of articles
published in 2013 in the American Journal
of Physiology–Cell Physiology, which
requires sex of cell lines to be reported,
demonstrated 20% of cell lines used to be
of male origin, 5% female, and the other
75% still unreported (29). To further
illustrate, of the most commonly used lung
epithelial cell lines reported in that
journal, both are of male origin. Yet male
sex has also been associated with reduced
alveolar epithelial sodium transport
capacity (30) and impaired regenerative
capacity after injury (31), demonstrating
the importance of accounting for cell sex
in respiratory research
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Role for Female Sex and
Gender in Specific Lung/Sleep
Diseases
Asthma
Asthma is caused by complex heterogeneous
pathological processes that affect the
airways (32). In females, asthma is
influenced by the rise during puberty, and
then fluctuating levels, of sex hormones.
Early-onset menarche resulting in greater
cumulative estrogen and progesterone
increases the risk of asthma (33). Asthma
incidence and hazard rate increases in
women on hormone replacement therapy,
and asthma worsens perimenstrually in
30–40% of females. Puberty also marks the
point in which women develop higher
adiposity and a greater ratio of leptin
to adiponectin, adipokines implicated
in asthma. These hormonal changes,
together with differences in airway size
(i.e., dysanapsis [34]), contribute to the
higher asthma prevalence in women.
Clinically, women have more frequent and
severe asthma symptoms, poorer quality of
life, greater healthcare utilization, greater
likelihood of hospitalization, and a higher
mortality rate (35). The Severe Asthma
Research Program showed that asthma is
worse in boys than in girls and in women
than in men. Androgens are generally
associated with higher lung function in
asthma; in a large Norwegian population
study, lower FEV1 was associated with
lower testosterone (36). Similar findings
were observed in a large Australian cohort
(37). Inhaled dehydroepiandrosterone
(DHEA) improves asthma symptoms (38).
Testosterone can promote airway smooth
muscle relaxation. DHEA inhibits human
airway smooth muscle and fibroblast
proliferation, and is a bronchodilator in
guinea pigs (39). In the Severe Asthma
Research Program cohort, endocrine
substudies revealed differences in levels of
DHEA and testosterone associated with the
severe asthma phenotype. Surprisingly,
both males and females with severe asthma
improve in adolescence, but asthma severity
increases among women in adulthood.
These facts underscore the need to better
understand asthma in females, taking into
account not only the cellular and tissue-
specific alterations, but also the interplay
of the complex hormonal milieu and the
impact of sex/gender (40).
CF
CF is an autosomal recessive disease
that results in progressive airway
obstruction and is characterized by chronic
inflammation and infection of the lungs.
Although equally prevalent in males and
females, females exhibit a decreased life span
due to complications of more severe lung
disease. The United States CF Foundation
patient registry showed a sex disparity
with regard to median life expectancy,
which was found to be nearly 3 years
shorter in females (41). Females with
CF after puberty also have a higher
rate of pulmonary exacerbations (42).
Furthermore, Pseudomonas aeruginosa is
acquired by females with CF earlier in life,
and is associated with a more rapid decline
in lung function (43). Interestingly,
although females with CF receive lung
transplantation at a younger age than
males, the post-transplantation survival
is equal between sexes regardless of the
sex of the donor lung (44). Discrepancies
in adherence, access to care, size of
the airways, and activity or exercise
levels may account for some of the
differences. Existing data also implicate
sex hormone–mediated effects on CF
lung disease. One hypothesis is that
17b-estradiol contributes to worse
female outcomes through modulation of
bacterial morphology, airway epithelial ion
channels, inflammation, and neutrophil
functions. 17b-estradiol induces a mucoid
conversion of P. aeruginosa in vitro,
and higher levels of 17b-estradiol are
associated with increased exacerbations
in CF (15). 17b-estradiol affects uridine
triphosphate–induced chloride secretion on
airway epithelium, resulting in a further
decreased air surface liquid layer in females
(45). 17b-Estradiol induces marked
impairment in P. aeruginosa–killing
capacity by neutrophils, correlating with
an exaggerated inflammatory response
(46). The effects of other sex hormones,
including progestin and androgen, have not
been thoroughly evaluated in CF. These
data show that CF may provide a model
disease to understand differences in male
and female outcomes in a lung disease. The
robust national registry supported by the
CF Foundation can track the influence of
sex hormones across the lifespan, and a
large subset of lung transplant data allows
for analysis of the impact of transplant sex
mismatch.
COPD
COPD is a complex condition, characterized
by progressive and largely irreversible
airflow limitation (47). Although COPD
affects both men and women, COPD
prevalence is increasing more rapidly in
women, particularly in younger women
(48). In the United States, COPD-related
hospitalizations and deaths in women
now also surpass those in men (48).
Women also predominate the roughly
25% of nonsmokers with COPD (49).
Sex-specific susceptibility to COPD is
poorly understood; however, published data
suggest that women are more susceptible to
tobacco smoke (48). Women with COPD
also face challenges related to their interface
with the healthcare system. Women are
more likely to be misdiagnosed (50), and
survey data also suggest that women are
more likely to perceive a delay in diagnosis,
attributing it to lack of availability of
providers and poor insurance (51).
Although individuals with COPD tend to
have lower socioeconomic status than those
without COPD, income for women with
COPD tends to be even lower than that for
men. It is not known exactly what impact
this has on the ability to obtain appropriate
care and other clinical outcomes. Multiple
studies outside of COPD demonstrate
that women in general are less likely to
be adherent to medication, which could
also impact disease presentation and
management (52). Although socioeconomic
factors certainly could influence adherence,
differences appear to persist even after
adjusting for socioeconomic factors (53).
Women report more dyspnea than
men despite similar lung function testing
and fewer pack years of smoking (54).
Factors that may contribute include
greater prevalence of anxiety and
depression and increased frequency
of COPD exacerbations in women
(54, 55). Differences for COPD risk and
manifestations are likely multifactorial:
smaller lung size in women, estrogen
impacts on xenobiotic metabolism of
cigarette smoke, and environmental
exposures may also contribute. In addition,
the perimenopausal period represents a
time of significant lung function decline
in women. Molecular analyses suggest sex
differences in inflammatory burden. Sex-
specific genetic and epigenetic associations,
gene-by-smoking interactions, and X
chromosome associations all contribute to
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the differential impact in women. These
findings present an opportunity for the
development of sex-specific therapeutics.
Multiple studies suggest that it is more
difficult for women to quit smoking, but
data from the Lung Health Study also
suggest that smoking cessation results in
greater lung function improvement for
women (56). Additional data from the Lung
Health Study also suggest greater FEV1
response to inhaled ipratropium for
women, possibly due to greater M3
relative to M2 receptor expression in
women (57), and a pooled analysis of
indacaterol/glycopyrronium studies
reported greater quality-of-life
improvements in women (58). Taken
together, the compendium of evidence
suggests that gender-specific approaches
to COPD are imperative. As gender is
clearly multidimensional, systems-based
analytic approaches may also allow us to
refine early diagnosis, therapeutics, and
primary prevention to account for these
differences (59).
Pulmonary Fibrosis
Interstitial lung diseases are a heterogeneous
group of disorders that are increasing in
prevalence. The most common of these
diseases, idiopathic pulmonary fibrosis
(IPF), displays evidence of sexual
dimorphism (60). Men are affected by IPF
more than women, and female sex is
predictive of better outcomes in IPF,
including outcomes with surgical lung
biopsy, lung transplantation over the age of
65 years, and overall survival (61–63).
However, women are more burdened by
the symptoms of IPF compared with men,
and have worse health-related quality of life
(64). There have been a few animal models
of pulmonary fibrosis that have sought to
understand this sexual dimorphism, mostly
pointing toward the adverse effect of
testosterone (65). However, confirmatory
studies in humans are absent. Interestingly,
in one population-based case–control
study, the adverse effect of smoking on
development of severe pulmonary fibrosis
was amplified by male gender (66). The
other main group of ILDs that display
sexual dimorphism in regard to prevalence
and natural history are the autoimmune-
related interstitial lung diseases. Young
women are most commonly affected by this
condition, yet men who get this disease
generally have a worse natural history
compared with women (67).
Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a
destructive, progressive lung disease that
can lead to respiratory failure in young
women. LAM is caused by inactivating
mutations in the tuberous sclerosis complex
(TSC) genes, TSC1 and TSC2, leading to
activation of mTORC1 (68). For reasons
that are incompletely understood, but
possibly associated with estrogen pathways,
LAM affects women almost exclusively,
with one of the strongest gender
predispositions of all human diseases,
except for diseases of the genital organs
(69, 70). LAM progresses more rapidly in
premenopausal women, further supporting
a key role of hormonal factors. It is believed
that LAM cells originate outside the lungs,
although the precise site of origin is not
established; the uterus, pericytes, and neural
crest are candidates. Both cell-autonomous
effects of hormones on cell proliferation and
metabolism, and non–cell-autonomous effects
on lymphangiogenesis and the destruction
of lung parenchyma are likely to contribute
to LAM pathogenesis. Recent data show
that targeting estrogen receptors may be
efficacious in the treatment of LAM (71).
Pulmonary Hypertension
Pulmonary arterial hypertension (PAH), a
progressive cardiopulmonary disease that
involves remodeling and vasoconstriction of
vessels in the lung, is a sexually dimorphic
disease more common in women (72).
Despite female preponderance of disease
development, female patients with PAH
exhibit better survival than males (73, 74).
This puzzling observation has been termed
the “estrogen paradox” of PAH. An
additional estrogen paradox in PAH
research centers on the fact that estrogens
have been shown to be protective in several
animal models of PAH, an observation that
is opposed to the clinical finding of female
susceptibility to disease development (72).
On the other hand, animal studies exist
in which estrogens (in particular, 16a-
hydroxyestrone) have been linked to
disease development (72). The reasons
for the discrepancy are unclear, but it is
likely that differences in experimental
models used, differences in estrogen
delivery, and/or differences in the age
of experimental animals contribute to
these findings. The underlying etiology
of PAH/pulmonary hypertension (PH),
the presence of genetic alterations (e.g.,
mutations in the BMPR2 gene) and the
stage of the disease (early vs. late) may
determine whether estrogens are beneficial
or harmful in PAH. In humans with
established PAH, it is clear that sex affects
success of some PAH-directed therapies,
in addition to survival (75, 76). A fairly
uniform body of evidence suggests that
17b-estradiol has important direct and
indirect effects on right ventricular (RV)
function, which allow for better RV
adaptation to the PAH-induced increase
in RV afterload (72). The etiology of the
observed sex-based difference in treatment
responses is presently unknown.
Sleep-disordered Breathing
Sleep-disordered breathing (SDB) is a
serious medical condition characterized by
recurrent episodes of airway closure and
reopening during sleep, typically resulting in
intermittent hypoxia, elevated sympathetic
tone, oxidative stress, as well as fragmented
and poor sleep quality (77). Sleep apnea is
associated with an array of disease risks and
outcomes common in women, including
hypertension, myocardial infarction, heart
failure, stroke, diabetes, cancer, depression,
dementia, and quality-of-life measures
(77). Women tend to report different
sleep apnea symptoms than men, more
commonly noting insomnia, fatigue, and/or
depressive symptoms, rather than the more
traditional symptoms of chronic snoring
and gasping for air during sleep (78). Sleep
questionnaires are not routinely designed
and validated taking sex differences in SDB
clinical presentation into consideration.
Women are less likely than men to seek
medical attention for concerns about SDB,
and medical professionals less likely to
recognize women’s symptoms of SDB,
leaving the large majority of women with
SDB undiagnosed and untreated (78, 79).
There is a critical need to improve the
identification of patient-reported symptoms
and physiological risk factors of SDB in
women to reduce the number of undiagnosed
cases.
The severity of SDB generally differs in
women compared with men, including a
lower apnea–hypopnea index, shorter
duration of individual apnea/hypopnea
events, less oxygen desaturation, and
greater occurrence of airflow limitation
accompanied by microarousals from sleep
(79). Although sleep apnea is overall less
prevalent in women, susceptibility increases
with overweight/obesity, and during
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particular life stages, including pregnancy
and menopause (78). Research is needed to
more completely understand mechanisms
underlying sex differences in the etiology of
SDB, including upper airway anatomy,
neuromuscular function, sex hormone
effects on ventilatory control, and genetic
susceptibility. For example, sex-specific
differences have been identified in the
sleep-state–dependent hypoxic ventilatory
response (80). RAI1 and obstructive sleep
apnea–related quantitative trait locus in
men, but not women, suggest that different
biologic pathways may be involved in the
etiology of SDB in men compared with
women (81).
Although epidemiologic findings point
to middle-aged men as most vulnerable to
sleep apnea–related mortality and coronary
heart disease, recent findings point to an
array of SDB-associated cardiometabolic
risks in women (79), with even greater
susceptibility to elevated hs-troponin
levels, increased left ventricular mass,
incident heart failure, impaired endothelial
function, and brain white matter loss
(79, 82–84). Emerging experimental
intermittent hypoxia models support a
link between estradiol and SDB-triggered
cardiopulmonary dysfunction (85). In
addition, associations of SDB with
cardiovascular and metabolic outcomes in
pregnancy, such as pre-eclampsia and
gestational diabetes, have been consistently
described (86, 87), both conditions
anticipating cardiovascular and metabolic
disease later in life. Maternal SDB is linked
to adverse neonatal outcomes that are
associated with long-term morbidity in
the offspring, such as preterm birth and
possibly growth restriction (86). The effect
of SDB exposure (e.g., oxidative stress,
inflammation, sympathetic drive) on
mechanisms of placental function and in
utero development are not well understood.
A better understanding of SDB-triggered
mechanisms of pathobiology in women is
needed to identify intermediate markers
and therapeutic targets to mitigate SDB risk
to women’s health. SDB is frequently
comorbid with insomnia, depression,
fatigue, asthma, and chronic pain, and may
contribute to the etiology, severity, and the
ability to effectively treat these conditions
(78, 79). In summary, SDB is a risk factor
for many conditions affecting women, and
needs to be considered as an important
variable in research studies, and evaluated
as a key factor in the health of women.
Conclusions and Future
Perspectives
One of the most important issues on which
biomedical researchers and social scientists
can collaborate is defining the mechanisms
by which the environment modifies the
phenotype, central to which is the interplay
between sex and gender. This report
highlights variations in disease prevalence,
presentation, and progression that may be
mediated by biological or social factors, or
both. Personalized medicine will not advance
without inclusion of the roles of sex/gender
in biology and pathobiology (88). A key goal
of the workshop was to develop a list of
future recommendations to advance our
understanding of the roles of sex and
gender in sleep and lung diseases, as
outlined in Table 1. Although multiple
recommendations were developed, top
priorities that could be implemented within
the next few years include, first, the need
for guidelines standardizing reporting of
sex for cellular and animal models.
Second, the participants recommend that
Table 1. Workshop Recommendations
Key recommendations:
d Establish guidelines/standardization encompassing sex for reporting of cellular and animal
models for in vitro experiments
d Develop multidisciplinary platforms, with the inclusion of endocrinologists, for
understanding sex steroid expression and signaling in both basic and clinical
research
d Encourage the reporting of sex-stratified analyses when possible (as supplemental tables),
to allow future meta-analyses of sex differences
d Train pulmonary researchers in big data methods that accommodate systems biology and
network modeling of sex and gender and their impact on lung diseases and sleep
disorders
Additional recommendations:
Basic research
d Include female animals and take into account the estrous cycle of the female mice in
all modeling of lung/sleep disorders
d Microbiome studies should incorporate sex as a variable and address causal
pathways by which sex/gender influences the structure and function of the
microbiome, including metabolomics and transcriptomics
d Develop a multi-institutional “biobank” specific to exploration of women’s lung and
sleep health and promote sex-specific analysis of genome-wide association studies
in various populations
Clinical research
d Perform preclinical and clinical trials to determine how hormonally based therapies
can be used to benefit women with lung diseases and sleep disorders
d Understand the impact of gender on symptoms of disease and therapeutic
choices
d Understand the impact of sex and gender on side-effect sensitivities to therapies,
including pharmacologic and nonpharmacologic (e.g., oxygen, pulmonary
rehabilitation) options, and drug metabolism
d Study the effects of modifying factors, such as age, menopausal state, and nutrition,
on sex hormone signaling in pulmonary diseases and sleep disorders
d Clarify how gender disparities in comorbidities of lung diseases/sleep disorders may
impact disease progression and prognosis
d Clarify the impact of hormone contraceptive therapy and hormone replacement
therapy on lung diseases/sleep disorders
d Study in detail sex hormones, ratios, and metabolites other than estrogens
d Study of how sex/gender may mechanistically alter drug responses
Training
d Train pulmonary care providers in the biological, environmental, and psychosocial
aspects of gender as it relates to lung disease/sleep disorders
d Train pulmonary care providers about sex differences in lung biology and
pathobiology/sleep disorders, and their manifestations across the life course,
including susceptibility, presentation, and severity of disease
d Train pulmonary care providers in the chromosomal and endocrinological differences
that may drive health effects in lung diseases/sleep disorders
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multidisciplinary platforms, particularly
including endocrinologists, be developed
to encourage broader understanding
regarding the role of sex steroids in
the mechanisms of health and disease.
The workshop itself brought together
individuals with a wide variety of research
focus and expertise. These types of
collaborative efforts will be crucial
to expanding our understanding
the role of sex and gender. A third
recommendation is that clinical trials
report sex-stratified analyses when
possible to allow for future meta-
analyses, which would be fairly easy
to implement. Fourth, we must
leverage new scientific advancements,
including gene editing and epigenetic
modifications. We now know that
genetic expression is moderated
through epigenetics, not confined to the
methylation of DNA only. Some examples
of epigenetic phenomena/action include
X chromosome inactivation, sex-specific
gene expression in tissues during
development, the creation of the
sex-specific setting for disease later
in life, and the establishment of the
machinery for the heredity of epigenetic
modifications. Societal trends, where
chromosomal and hormonal sex are
mismatched, may also represent an
opportunity to clarify the role of sex
versus gender in health and disease.
Finally, we must enhance the training
for future researchers in big data methods
that accommodate systems biology and
network modeling of sex and gender and
their impact on sleep and lung disease. n
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